193P Sensitivity of homologous recombination deficient sarcoma to DNA damage response targeting drugs
Abstract
Defects in the homologous recombination repair (HRR) pathway have been frequently observed in high-grade ovarian, breast, pancreatic and prostate carcinomas. HRR deficiency (HRD) has emerged as a key therapeutic vulnerability by exploiting the concept of synthetic lethality. Targeting PARP proteins causes cells to rely on other pathways for repairing double-strand DNA breaks. When cells lack functional BRCA1/2 genes or exhibit a compromised HRR pathway, they become sensitive to PARP inhibition (PARPi), while cells with an intact HRR pathway are unaffected.
Fields of Study & Subjects
PARP inhibition in cancer therapy
DNA Repair Mechanisms
BRCA gene mutations in cancer
Publication details
- Journal / source
- ESMO rare cancers.
- Volume
- 5
- Pages
- 100399–100399
- Publication date
- 1 March 2026
- Language
- EN